Drug intelligence / Profile preview

GAIA-121-125 (C+)

Development stage: Preclinical
Lead developer: GAIA BioMedicine
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**GAIA-121-125 (C+)** is a preclinical, intravenous allogeneic NK-like cell therapy from GAIA BioMedicine for solid tumors expressing the company-designated proprietary tumor antigen C+. It uses GAIA's GAAAP antibody-armed adoptive cell therapy platform, in which peripheral blood mononuclear cell-derived NK-like cells are armed with a proprietary antibody intended to direct cytotoxic activity toward C+-expressing tumor cells. The molecular identity of antigen C+ and the corresponding arming antibody have not been publicly disclosed.

Other names: GAIA-121-125 C+

Beyond the preview

Go deeper on GAIA-121-125 (C+).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAIA-121-125 (C+).

Explore the full profile